Scarica l'app Stockscreener
0.1056
3.63%
0.0037
Pre-mercato:
.10
-0.0056
-5.30%
Precedente Chiudi:
$0.1019
Aprire:
$0.103
Volume 24 ore:
12.70M
Relative Volume:
0.55
Capitalizzazione di mercato:
$6.07M
Reddito:
-
Utile/perdita netta:
$-17.06M
Rapporto P/E:
-0.00149
EPS:
-70.7173
Flusso di cassa netto:
$-14.18M
1 W Prestazione:
-1.58%
1M Prestazione:
-2.22%
6M Prestazione:
-89.94%
1 anno Prestazione:
-99.73%
Intervallo 1D:
$0.10
$0.1059
Intervallo di 1 settimana:
$0.10
$0.114
Portata 52W:
$0.0955
$34.50
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Confronta CNSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
0.1056 | 6.07M | 0 | -17.06M | -14.18M | -70.72 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
CNS Pharma (NASDAQ:CNSP) Stock Quotes, Forecast and News Summary - Benzinga
CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN
Central Nervous System (CNS) Therapeutics Market Forecast - GlobeNewswire
Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region - 24matins.uk
CNS Pharmaceuticals (NASDAQ:CNSP) Trading Up 6.5% – Here’s Why - Defense World
Cns Pharmaceuticals Inc (CNSP-Q) QuotePress Release - The Globe and Mail
Does Cns Pharmaceuticals Inc (NASDAQ: CNSP) Still Need To Convince Analysts? - Stocks Register
CNS Drug-Maker Reviva Announces $18M Public Offering of Common Stock and Warrants to Fund R&D - geneonline
Trevena's SWOT analysis: CNS drug developer's stock faces pivotal moment - Investing.com
CNS Pharmaceuticals Announces Upcoming Virtual Analyst and Investor Day - Defense World
Cns Pharmaceuticals Inc (NASDAQ: CNSP): An Enticing Stock To Watch - Stocks Register
CNS Pharmaceuticals Hosts Virtual Analyst and Investor Day - Nasdaq
CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11 - Barchart
CNS Pharmaceuticals sets date for virtual investor event By Investing.com - Investing.com Nigeria
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 - AccessWire
CNS Pharmaceuticals to Host Virtual Investor Day: Spotlight on Breakthrough Brain Cancer Treatments - StockTitan
CNS Pharmaceuticals gains shareholder nod for reverse split, warrant repricing - Investing.com
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy - AccessWire
CNS Pharma's Berubicin Shows Higher Patient Retention in Pivotal GBM Trial | CNSP Stock News - StockTitan
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment - GuruFocus.com
CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Down 4.3% – Here’s What Happened - Defense World
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting - Barchart
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment With Berubicin - Barchart
CNS Pharmaceuticals to Present Berubicin GBM Trial Data at SNO 2024 Annual Meeting | CNSP Stock News - StockTitan
CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) - AccessWire
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results - AccessWire
CNS Pharmaceuticals Completes 252-Patient Enrollment in Pivotal Brain Cancer Study | CNSP Stock News - StockTitan
CNS Pharmaceuticals Inc (CNSP) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in CNS Pharmaceuticals Inc - GuruFocus.com
CNS Pharmaceuticals: Financial Results and Strategic Moves - TipRanks
ACADIA Pharmaceuticals' SWOT analysis: mixed results for CNS drug stock - Investing.com
CNS Pharmaceuticals’ $3 Million Common Stock Offering - Global Legal Chronicle
Reviva Pharma to Present Breakthrough Phase 3 Schizophrenia Drug Data at CNS Summit - StockTitan
Sage Therapeutics' SWOT analysis: stock faces challenges amid CNS drug market shifts - Investing.com
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment - AccessWire
CNS Pharmaceuticals Receives Temporary Exception from NASDAQ Regarding Minimum Bid Price Requirement - Defense World
CNS Pharmaceuticals granted Nasdaq compliance extension By Investing.com - Investing.com South Africa
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Yahoo Finance
CNS Pharmaceuticals granted Nasdaq compliance extension - Investing.com
CNSPCNS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation - The Manila Times
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - Financial Content
CNS Pharmaceuticals faces NASDAQ delisting over price rule By Investing.com - Investing.com Australia
CNS Pharmaceuticals secures $3 million in registered direct offering - Investing.com
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cns Pharmaceuticals Inc Azioni (CNSP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Evans Carl Anthony | Director |
Feb 01 '24 |
Buy |
0.30 |
33,333 |
10,000 |
33,458 |
| Downs Christopher | Chief Financial Officer |
Feb 01 '24 |
Buy |
0.30 |
66,666 |
20,000 |
103,438 |
| Climaco John M | Chief Executive Officer |
Feb 01 '24 |
Buy |
0.30 |
166,666 |
50,000 |
215,676 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):